A screening algorithm to identify clinically significant changes in neuropsychological functions in the Diabetes Control and Complications Trial. DCCT Research Group

Neurocognitive disturbances in HIV

HIV infection is associated with disturbances in brain function which reflect themselves in HIV associated neurocognitive disorder (HAND). Neurocognitive examination is a sensitive and relevant approach to detecting and monitoring HAND. The approaches to evaluating the various neurocognitive disturbances are reviewed, along with consideration of cofactors that may influence expression of these disorders.

Evaluating the Effects of Treatment for Medical Disorders: Has the Value of Neuropsychological Assessment Been Fully Realized?

Cognitive functioning can be affected by medical disorders and by the regimens used to treat them. To evaluate the cognitive risks and benefits of specific medical treatments, an increasing number of medical clinical trials have included a formal neuropsychological evaluation. This selective review has three goals: (a) to survey the range of assessment techniques used with different patient populations (e.g., those with diabetes, chronic obstructive pulmonary disease [COPD], hypertension, HIV, or cardiac disease) and treatment regimens (e.g., medical management, pharmacotherapy, surgery), (b) to demonstrate how cognitive outcome measures can contribute to an understanding of the value of certain treatments, and (c) to identify critical conceptual and methodological problems. The utility of this approach is incontrovertible-most large-scale medical trials have found either no adverse cognitive side effects or improved cognitive functioning following treatment. Nevertheless, before cognitive measures are routinely included in medical clinical trials, investigators will have to resolve problems that include the measurement of behavior change over time and the identification of clinically significant impairment.

The HNRC 500--neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center

The present study examined neuropsychological (NP) functioning and associated medical, neurological, brain magnetic resonance imaging (MRI), and psychiatric findings in 389 nondemented males infected with Human Immunodeficiency Virus-Type 1 (HIV-1), and in 111 uninfected controls. Using a comprehensive NP test battery, we found increased rates of impairment at each successive stage of HIV infection. HIV-related NP impairment was generally mild, especially in the medically asymptomatic stage of infection, and most often affected attention, speed of information processing, and learning efficiency; this pattern is consistent with earliest involvement of subcortical or frontostriatal brain systems. NP impairment could not be explained on the bases of mood disturbance, recreational drug or alcohol use, or constitutional symptoms; by contrast, impairment in HIV-infected subjects was related to central brain atrophy on MRI, as well as to evidence of cellular immune activation and neurological abnormalities linked to the central nervous system.

Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group

The Diabetes Control and Complications Trial has demonstrated that intensive diabetes treatment delays the onset and slows the progression of diabetic complications in subjects with insulin-dependent diabetes mellitus from 13 to 39 years of age. We examined whether the effects of such treatment also occurred in the subset of young diabetic subjects (13 to 17 years of age at entry) in the Diabetes Control and Complications Trial. One hundred twenty-five adolescent subjects with insulin-dependent diabetes mellitus but with no retinopathy at baseline (primary prevention cohort) and 70 adolescent subjects with mild retinopathy (secondary intervention cohort) were randomly assigned to receive either (1) intensive therapy with an external insulin pump or at least three daily insulin injections, together with frequent daily blood-glucose monitoring, or (2) conventional therapy with one or two daily insulin injections and once-daily monitoring. Subjects were followed for a mean of 7.4 years (4 to 9 years). In the primary prevention cohort, intensive therapy decreased the risk of having retinopathy by 53% (95% confidence interval: 1% to 78%; p = 0.048) in comparison with conventional therapy. In the secondary intervention cohort, intensive therapy decreased the risk of retinopathy progression by 70% (95% confidence interval: 25% to 88%; p = 0.010) and the occurrence of microalbuminuria by 55% (95% confidence interval: 3% to 79%; p = 0.042). Motor and sensory nerve conduction velocities were faster in intensively treated subjects. The major adverse event with intensive therapy was a nearly threefold increase of severe hypoglycemia. We conclude that intensive therapy effectively delays the onset and slows the progression of diabetic retinopathy and nephropathy when initiated in adolescent subjects; the benefits outweigh the increased risk of hypoglycemia that accompanies such treatment.